Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter, despite missing the company’s ...

International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the ...

Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

Fast-food restaurant owner Yum Brands is expecting stronger sales growth this year after it moves past challenges in its Middle East markets.

Chipotle Mexican Grill said on Tuesday that if President Donald Trump's proposed tariffs on Mexico go into full effect, the ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Veralto Corporation delivered all-time high annual sales of $5.2 billion in 2024, with 3.7% core sales growth and an adjusted earnings per share increase of 11% to $3.54. Free cash flow generation ...

Q4 2024 Management View CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and ...

Be cautious ahead of Canopy Growth Corporation's FQ3 results, as weak financials and low margins may hinder stock performance ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.